FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365149214> ?p ?o ?g. }

• W4365149214 endingPage "1124" @default.
• W4365149214 startingPage "1115" @default.
• W4365149214 abstract "Esomeprazole, a proton pump inhibitor (PPI), is widely used to treat acid-related disorders, but it has short plasma half-life which can cause insufficient gastric acid suppression, such as nocturnal acid breakthrough. A new dual delayed-release (DR) formulation of esomeprazole (Esomezol DR), was developed to extend the duration of gastric acid suppression.This study aimed to evaluate the pharmacokinetics (PKs) and pharmacodynamics (PDs) of esomeprazole for the DR formulation compared to a conventional enteric-coated (EC) formulation (Nexium) in healthy male subjects.Two randomized, open-label, multiple-dose, two-way crossover studies with esomeprazole 20 mg and 40 mg were conducted. Subjects received the DR formulation or the EC formulation once daily for 7 days in each period with a 7-day washout. Serial blood samples were collected up to 24 hours after the 1st dose, and 24-hour intragastric pH was continuously monitored before the 1st dose as baseline and after the 1st and the 7th dose.In 20 mg and 40 mg dose groups, 38 and 44 subjects completed the study, respectively. The DR formulation exhibited the dual-release pattern of esomeprazole, resulting in more sustained plasma concentration-time profiles compared to the EC formulation. The systemic exposure of esomeprazole for the DR formulation was comparable to that for the EC formulation, showing the similar area under the plasma concentration-time curve. The 24-hour gastric acid suppression was also similar between the two formulations, while the inhibition during night-time (22:00-06:00) showed a better tendency in the DR formulation.The sustained exposure of esomeprazole in the DR formulation led to well-maintained and higher acid inhibition compared to the EC formulation, especially during the night-time. These results suggest that the DR formulation can be an alternative formulation to the conventional EC formulation, expecting the potential of relieving nocturnal acid-related symptoms." @default.
• W4365149214 created "2023-04-13" @default.
• W4365149214 creator A5007929151 @default.
• W4365149214 creator A5016244479 @default.
• W4365149214 creator A5017967395 @default.
• W4365149214 creator A5020942494 @default.
• W4365149214 creator A5028454019 @default.
• W4365149214 creator A5064370332 @default.
• W4365149214 creator A5067351078 @default.
• W4365149214 creator A5072556204 @default.
• W4365149214 date "2023-04-01" @default.
• W4365149214 modified "2023-09-26" @default.
• W4365149214 title "Pharmacokinetics and Pharmacodynamics of Esomezol DR, a New Dual Delayed-Release Formulation of Esomeprazole 20 Mg or 40 Mg, in Healthy Subjects" @default.
• W4365149214 cites W1568350882 @default.
• W4365149214 cites W1956992458 @default.
• W4365149214 cites W1982227541 @default.
• W4365149214 cites W1983300063 @default.
• W4365149214 cites W1994362210 @default.
• W4365149214 cites W1994797593 @default.
• W4365149214 cites W2002931087 @default.
• W4365149214 cites W2014408183 @default.
• W4365149214 cites W2015402531 @default.
• W4365149214 cites W2018382485 @default.
• W4365149214 cites W2024697584 @default.
• W4365149214 cites W2025582787 @default.
• W4365149214 cites W2027852470 @default.
• W4365149214 cites W2028897395 @default.
• W4365149214 cites W2045430029 @default.
• W4365149214 cites W2061056188 @default.
• W4365149214 cites W2064517127 @default.
• W4365149214 cites W2089407496 @default.
• W4365149214 cites W2120175186 @default.
• W4365149214 cites W2120230272 @default.
• W4365149214 cites W2142317898 @default.
• W4365149214 cites W2147199669 @default.
• W4365149214 cites W2157908996 @default.
• W4365149214 cites W2167344139 @default.
• W4365149214 cites W2168234648 @default.
• W4365149214 cites W2171444389 @default.
• W4365149214 cites W2550831966 @default.
• W4365149214 cites W2760177571 @default.
• W4365149214 cites W2785608288 @default.
• W4365149214 cites W2966289668 @default.
• W4365149214 cites W3216394740 @default.
• W4365149214 cites W4200578542 @default.
• W4365149214 cites W4283824868 @default.
• W4365149214 doi "https://doi.org/10.2147/dddt.s392533" @default.
• W4365149214 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37077412" @default.
• W4365149214 hasPublicationYear "2023" @default.
• W4365149214 type Work @default.
• W4365149214 citedByCount "0" @default.
• W4365149214 crossrefType "journal-article" @default.
• W4365149214 hasAuthorship W4365149214A5007929151 @default.
• W4365149214 hasAuthorship W4365149214A5016244479 @default.
• W4365149214 hasAuthorship W4365149214A5017967395 @default.
• W4365149214 hasAuthorship W4365149214A5020942494 @default.
• W4365149214 hasAuthorship W4365149214A5028454019 @default.
• W4365149214 hasAuthorship W4365149214A5064370332 @default.
• W4365149214 hasAuthorship W4365149214A5067351078 @default.
• W4365149214 hasAuthorship W4365149214A5072556204 @default.
• W4365149214 hasBestOaLocation W43651492141 @default.
• W4365149214 hasConcept C111113717 @default.
• W4365149214 hasConcept C112705442 @default.
• W4365149214 hasConcept C126322002 @default.
• W4365149214 hasConcept C142724271 @default.
• W4365149214 hasConcept C181389837 @default.
• W4365149214 hasConcept C185592680 @default.
• W4365149214 hasConcept C204787440 @default.
• W4365149214 hasConcept C27081682 @default.
• W4365149214 hasConcept C2777504413 @default.
• W4365149214 hasConcept C2777570183 @default.
• W4365149214 hasConcept C2778204628 @default.
• W4365149214 hasConcept C2779422922 @default.
• W4365149214 hasConcept C2781025758 @default.
• W4365149214 hasConcept C71839028 @default.
• W4365149214 hasConcept C71924100 @default.
• W4365149214 hasConcept C77281830 @default.
• W4365149214 hasConcept C87813604 @default.
• W4365149214 hasConcept C90924648 @default.
• W4365149214 hasConcept C98274493 @default.
• W4365149214 hasConceptScore W4365149214C111113717 @default.
• W4365149214 hasConceptScore W4365149214C112705442 @default.
• W4365149214 hasConceptScore W4365149214C126322002 @default.
• W4365149214 hasConceptScore W4365149214C142724271 @default.
• W4365149214 hasConceptScore W4365149214C181389837 @default.
• W4365149214 hasConceptScore W4365149214C185592680 @default.
• W4365149214 hasConceptScore W4365149214C204787440 @default.
• W4365149214 hasConceptScore W4365149214C27081682 @default.
• W4365149214 hasConceptScore W4365149214C2777504413 @default.
• W4365149214 hasConceptScore W4365149214C2777570183 @default.
• W4365149214 hasConceptScore W4365149214C2778204628 @default.
• W4365149214 hasConceptScore W4365149214C2779422922 @default.
• W4365149214 hasConceptScore W4365149214C2781025758 @default.
• W4365149214 hasConceptScore W4365149214C71839028 @default.
• W4365149214 hasConceptScore W4365149214C71924100 @default.
• W4365149214 hasConceptScore W4365149214C77281830 @default.
• W4365149214 hasConceptScore W4365149214C87813604 @default.
• W4365149214 hasConceptScore W4365149214C90924648 @default.

• next